Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116,052 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer.
Zhang Y, Chen G, Chen X, Fang W, Gao F, Yang Y, Zhao Y, Ma Y, Hong S, Zhang Z, Miao S, Wu M, Huang X, Luo Y, Zhou C, Gong R, Huang Y, Chen L, Zhou N, Zhao H, Zhang L. Zhang Y, et al. Among authors: chen l, chen g, chen x. J Cancer. 2017 Jul 2;8(10):1865-1871. doi: 10.7150/jca.19867. eCollection 2017. J Cancer. 2017. PMID: 28819384 Free PMC article.
The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and meta-analysis.
Zhang Y, Miao S, Wang F, Fang W, Chen G, Chen X, Yan F, Huang X, Wu M, Huang Y, Zhang L. Zhang Y, et al. Among authors: chen g, chen x. J Thorac Dis. 2017 Jul;9(7):1980-1987. doi: 10.21037/jtd.2017.06.08. J Thorac Dis. 2017. PMID: 28839997 Free PMC article.
Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
Zhang Z, Zhang Y, Chen G, Hong S, Yang Y, Fang W, Luo F, Chen X, Ma Y, Zhao Y, Zhan J, Xue C, Hou X, Zhou T, Ma S, Gao F, Huang Y, Chen L, Zhou N, Zhao H, Zhang L. Zhang Z, et al. Among authors: chen l, chen g, chen x. Oncologist. 2018 May;23(5):603-616. doi: 10.1634/theoncologist.2017-0378. Epub 2018 Jan 12. Oncologist. 2018. PMID: 29330211 Free PMC article.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
116,052 results
You have reached the last available page of results. Please see the User Guide for more information.